Stock Price & Analysis

Based on the recent market data and news, TEVA stock is showing bearish signals with RSI at 26.99 indicating oversold conditions, but the recent mixed shelf offering announcement and disappointing 2025 guidance suggest continued downward pressure, making it advisable to wait for stabilization before considering a buy position.

Based on recent market data and analyst reports, TEVA stock is projected to reach $21-23 by end of 2025, driven by the successful execution of its Pivot to Growth strategy and positive developments in its innovative product pipeline. The stock faced significant pressure in early 2025 after disappointing guidance of $2.35-$2.65 EPS for 2025, but key assets like Austedo and Uzedy showing strong growth momentum could drive recovery. Technical analysis indicates strong resistance at $21.32 (Fibonacci R1) with current price at $16.675, suggesting potential upside of 25-35% from current levels if market sentiment improves and execution remains solid.

The S1 support level for TEVA Stock is $16.25 ,The R1 resistant level for TEVA Stock is $17.53.

As of the end of day on 2025-02-14, the price of TEVA Stock was $16.42.

The target price for TEVA Stock according to analyst rating is 24.50, with the highest price target at 30.00 and the lowest at 20.00. Analysts have a Strong Buy rating on TEVA Stock overall.

The market cap of TEVA is $18.4B.

Based on the provided data, I'll analyze whether TEVA is overvalued through multiple aspects:

Valuation Analysis TEVA's Q4 2024 valuation metrics show EV/EBITDA of 8.57x, P/S of 1.51x, and P/B of 4.65x . These metrics have been trending upward throughout 2024, suggesting increasing market expectations.

Financial Performance The company's financial health shows concerning trends:

• Net losses in all quarters of 2024, with Q4 2024 showing -$217M
• Declining gross margins from 51.48% in Q4 to 46.71% in Q1 2024
• High debt-to-equity ratio of 330.54% in Q4 2024
• Negative ROE trending worse from -6.31% to -25.45% throughout 2024

Analyst Perspective Recent analyst actions suggest mixed views but generally positive outlook:

• Barclays lowered PT to $26 from $28 while maintaining Buy rating
• UBS lowered PT to $27 from $30 while maintaining Strong Buy rating
• Multiple analysts see upside potential despite recent pullback

Conclusion TEVA is not overvalued considering its current market position, analyst targets showing 45-51% upside potential, and EV/EBITDA multiple below industry average. However, deteriorating financials and high debt levels present significant risks. Recent analyst downgrades reflect near-term challenges but maintain positive long-term outlook.

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Based on recent market performance and analyst projections, TEVA stock is expected to reach $25-28 by 2030, driven by successful execution of its Pivot to Growth strategy and promising developments in its innovative drug pipeline. The company's recent patent settlement with Axsome and strategic positioning in generic pharmaceuticals provides a strong foundation for long-term growth. However, near-term challenges including the disappointing 2025 guidance and margin pressures need to be navigated before realizing this long-term potential.

TEVA has a total of 35001 employees.